Nijmegen breakage syndrome: 25-year experience of diagnosis and treatment in Ukraine

• Published in: Frontiers in immunology Vol. 15; p. 1428724
• Main Authors: Boyarchuk, Oksana, Kostyuchenko, Larysa, Akopyan, Hayane, Bondarenko, Anastasiia, Volokha, Alla, Hilfanova, Anna, Savchak, Ihor, Nazarenko, Liliia, Yarema, Nataliia, Urbas, Olha, Hrabovska, Iryna, Lysytsia, Oleksandr, Budzyn, Andrii, Tykholaz, Oksana, Ivanchuk, Mariana, Bastanohova, Olha, Patskun, Erika, Vasylenko, Nataliia, Stepanovskyy, Yuriy, Chernyshova, Liudmyla, Makukh, Halyna
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 28-06-2024
• Subjects: Adolescent; Adult; c.657_661del5 variant; Child; Child, Preschool; diagnosis; Female; Humans; incidence; Infant; Male; malignancies; NBN gene; Nijmegen breakage syndrome; Nijmegen Breakage Syndrome - diagnosis; Nijmegen Breakage Syndrome - genetics; Nijmegen Breakage Syndrome - immunology; Nijmegen Breakage Syndrome - therapy; Prevalence; Registries; Retrospective Studies; Ukraine - epidemiology; Young Adult; Ukraine; immunological characterization; c.657_661del5 variant; Nijmegen breakage syndrome; malignancies; diagnosis; incidence; clinical analysis; NBN gene
• DOI: 10.3389/fimmu.2024.1428724
• EISSN: 1664-3224

Nijmegen breakage syndrome (NBS) is an autosomal recessive disorder, characterized by microcephaly, immunodeficiency, and impaired DNA repair. NBS is most prevalent among Slavic populations, including Ukraine. Our study aimed to comprehensively assess the prevalence, diagnosis, clinical data, immunological parameters, and treatment of NBS patients in Ukraine.
We conducted a retrospective review that included 84 NBS patients from different regions of Ukraine who were diagnosed in 1999-2023. Data from the Ukrainian Registry of NBS and information from treating physicians, obtained using a developed questionnaire, were utilized for analysis.
Among 84 NBS patients, 55 (65.5%) were alive, 25 (29.8%) deceased, and 4 were lost to follow-up. The median age of patients was 11 years, ranging from 1 to 34 years. Most patients originate from western regions of Ukraine (57.8%), although in recent years, there has been an increase in diagnoses from central and southeastern regions, expanding our knowledge of NBS prevalence. The number of diagnosed patients per year averaged 3.4 and increased from 2.7 to 4.8 in recent years. The median age of NBS diagnosis was 4.0 years (range 0.1-16) in 1999-2007 and decreased to 2.7 in the past 6 years. Delayed physical development was observed in the majority of children up to the age of ten years. All children experienced infections, and 41.3% of them had recurrent infections. Severe infections were the cause of death in 12%. The second most common clinical manifestation of NBS was malignancies (37.5%), with the prevalence of lymphomas (63.3%). Malignancies have been the most common cause of death in NBS patients (72% of cases). Decreased levels of CD4+ and CD19+ were observed in 89.6%, followed by a reduction of CD3+ (81.8%) and CD8+ (62.5%). The level of NK cells was elevated at 62.5%. IgG concentration was decreased in 72.9%, and IgA - in 56.3%. Immunoglobulin replacement therapy was administered to 58.7% of patients. Regular immunoglobulin replacement therapy has helped reduce the frequency and severity of severe respiratory tract infections.
Improvements in diagnosis, including prenatal screening, newborn screening, monitoring, and expanding treatment options, will lead to better outcomes for NBS patients.